论文部分内容阅读
骨肉瘤是最常见的原发于骨组织的成骨性恶性肿瘤,好发于青少年,恶性程度高,侵袭性强,早期易发生肺转移,预后较差,5年生存率不到20%,并且在过去的30年中治疗水平进展缓慢。手术曾是其唯一有效的治疗手段,后有研究表明,增加化疗药物剂量及配伍方面经过多项试验的尝试均未能提高生存获益,而其细胞生物学及分子发生机制也尚不明确[1]。因此,探究骨肉瘤的发生发展过程及生物学规律以优化现有的治疗策略是当务之急。最近研究证据表明,免疫系统
Osteosarcoma is the most common osteogenic malignant tumor that originates in bone tissue. It is predominant in adolescents. It has a high degree of malignancy, strong invasiveness, and early lung metastasis. The prognosis is poor. The 5-year survival rate is less than 20%. And the progress of treatment has been slow in the past 30 years. Surgery has been the only effective treatment method. Later studies have shown that attempts to increase doses and compatibility of chemotherapeutic drugs through multiple trials have failed to improve survival benefits, and their cell biology and molecular mechanisms are still not clear [ 1]. Therefore, it is imperative to investigate the occurrence and development process and biological rules of osteosarcoma to optimize the existing treatment strategies. Recent research evidence shows that the immune system